Abstract
Recent empirical studies and analyses have heightened interest in the use of expanded antiretroviral therapy (ART) for prevention of HIV transmission. However, ART is expensive, approximately $600 per person per year, raising issues of the cost and cost-effectiveness of ambitious ART expansion. The goal of this review is to equip the reader with the conceptual tools and substantive background needed to understand and evaluate the policy and programmatic implications of cost-effectiveness assessments of ART for prevention. We provide this review in six sections. We start by introducing and explaining basic concepts of health economics as they relate to this issue, including resources, costs, health metrics (such as Disability-Adjusted Life Years), and different types of economic analysis. We then review research on the cost and cost-effectiveness of ART as treatment, and on the cost-effectiveness of traditional HIV prevention. We describe critical issues in the epidemic impact of ART, such as suppression of transmission and the role of the acute phase of infection. We then present a conceptual model for conducting and interpreting cost-effectiveness analyses of ART as prevention, and review the existing preliminary estimates in this area. We end with a discussion of future directions for programmatic demonstrations and evaluation.
Keywords: Antiretroviral therapy, cost analysis, cost-effectiveness, economics, HIV prevention, HPTN, Cost-effectiveness analysis, Quality-Adjusted Life Years, ”, ART, CD4
Current HIV Research
Title: Cost-Effectiveness of Antiretroviral Therapy for Prevention
Volume: 9 Issue: 6
Author(s): James G. Kahn, Elliot A. Marseille, Rod Bennett, Brian G. Williams and Reuben Granich
Affiliation:
Keywords: Antiretroviral therapy, cost analysis, cost-effectiveness, economics, HIV prevention, HPTN, Cost-effectiveness analysis, Quality-Adjusted Life Years, ”, ART, CD4
Abstract: Recent empirical studies and analyses have heightened interest in the use of expanded antiretroviral therapy (ART) for prevention of HIV transmission. However, ART is expensive, approximately $600 per person per year, raising issues of the cost and cost-effectiveness of ambitious ART expansion. The goal of this review is to equip the reader with the conceptual tools and substantive background needed to understand and evaluate the policy and programmatic implications of cost-effectiveness assessments of ART for prevention. We provide this review in six sections. We start by introducing and explaining basic concepts of health economics as they relate to this issue, including resources, costs, health metrics (such as Disability-Adjusted Life Years), and different types of economic analysis. We then review research on the cost and cost-effectiveness of ART as treatment, and on the cost-effectiveness of traditional HIV prevention. We describe critical issues in the epidemic impact of ART, such as suppression of transmission and the role of the acute phase of infection. We then present a conceptual model for conducting and interpreting cost-effectiveness analyses of ART as prevention, and review the existing preliminary estimates in this area. We end with a discussion of future directions for programmatic demonstrations and evaluation.
Export Options
About this article
Cite this article as:
G. Kahn James, A. Marseille Elliot, Bennett Rod, G. Williams Brian and Granich Reuben, Cost-Effectiveness of Antiretroviral Therapy for Prevention, Current HIV Research 2011; 9 (6) . https://dx.doi.org/10.2174/157016211798038542
DOI https://dx.doi.org/10.2174/157016211798038542 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Central Role Played by Peptides in the Immune Response and the Design of Peptide-Based Vaccines Against Infectious Diseases and Cancer
Current Drug Targets 4-Mer Hyaluronan Oligosaccharides Stimulate Inflammation Response in Synovial Fibroblasts in Part via TAK-1 and in Part via p38-MAPK
Current Medicinal Chemistry Molecules of Parasites as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Synthesis of 2,4,6-Trichlorophenyl Hydrazones and their Inhibitory Potential Against Glycation of Protein
Medicinal Chemistry Strategies for Effective Naked-DNA Vaccination Against Infectious Diseases
Recent Patents on Anti-Infective Drug Discovery Truncated Human Cathepsin L, Encoded by a Novel Splice Variant, Exhibits Altered Subcellular Localization and Cytotoxicity
Protein & Peptide Letters Cytokines as Regulators of Atherosclerosis in Murine Models
Current Drug Targets A Novel Advanced Laboratory Diagnosis to Guide Tuberculosis Drug Therapy.
Recent Patents on Anti-Infective Drug Discovery Nanochemistry-Based Immunotherapy for HIV-1
Current Medicinal Chemistry Fragment Based Drug Design: From Experimental to Computational Approaches
Current Medicinal Chemistry SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Structural and Binding Properties of the Active Cell Wall Hydrolase RipA from <i>M. tuberculosis</i>, a Promising Biosensing Molecule for Early Warning Bacterial Detection
Current Medicinal Chemistry Immunological Mechanism and Clinical Application of PAMP Adjuvants
Recent Patents on Anti-Cancer Drug Discovery Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology Fragment-Based Drug Discovery and Molecular Docking in Drug Design
Current Pharmaceutical Biotechnology Anti-Arthritic Effects of Immunomodulatory Peptide Injected in Joints
Current Drug Delivery Synthesis and Evaluation of New Thiazole Derivatives as Potential Antimicrobial Agents
Letters in Drug Design & Discovery SV40 and HIV Sequences in the Cerebrospinal Fluid of a Patient with AIDS Dementia Complex
Current HIV Research Mycobacterium tuberculosis Treatment Modalities and Recent Insights
Current Drug Delivery